NASDAQ:EWTX Edgewise Therapeutics Q1 2025 Earnings Results & Report $45.93 +0.11 (+0.24%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$45.97 +0.04 (+0.09%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Edgewise Therapeutics beat analyst earnings expectations in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.43 versus the -$0.45 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 8, 2025TimeBefore Market OpensConference Call9:30 AM ET Edgewise Therapeutics EPS ResultsActual EPS-$0.43Consensus EPS -$0.45Beat/MissBeat by +$0.02One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEdgewise Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Edgewise Therapeutics Q1 2025 Earnings FAQ Did Edgewise Therapeutics beat earnings estimates for Q1 2025? Edgewise Therapeutics (NASDAQ:EWTX) reported earnings of -$0.43 per share for Q1 2025, beating the consensus estimate of -$0.45. The report was announced on Thursday, May 8, 2025. Edgewise Therapeutics Earnings HeadlinesResearch Analysts Offer Predictions for EWTX FY2028 EarningsNovember 13 at 2:13 AM | americanbankingnews.comEdgewise Therapeutics to Participate in Upcoming Investor ConferencesNovember 9, 2026 | prnewswire.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 14 at 1:00 AM | Base Camp Trading (Ad)Equities Analysts Issue Forecasts for EWTX FY2026 EarningsNovember 9, 2026 | americanbankingnews.comEdgewise Therapeutics (EWTX) Receives a Hold from Stifel NicolausNovember 8, 2026 | theglobeandmail.comEdgewise Therapeutics (EWTX) Receives a Buy from H.C. WainwrightNovember 8, 2026 | theglobeandmail.comSee More Edgewise Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Edgewise Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edgewise Therapeutics and other key companies, straight to your email. Email Address About Edgewise TherapeuticsEdgewise Therapeutics (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions. Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy. These therapies remain in clinical development and are not approved medicines. Edgewise is led by co-founder, President and Chief Executive Officer Kevin Koch. Its work is focused on advancing its drug candidates through clinical trials rather than marketing commercial products.View Edgewise Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
